These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


389 related items for PubMed ID: 7816064

  • 1. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M.
    N Engl J Med; 1995 Feb 02; 332(5):292-7. PubMed ID: 7816064
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators.
    Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, Saibil F, Groll A, Archambault A, Gillies R.
    N Engl J Med; 1994 Jun 30; 330(26):1846-51. PubMed ID: 8196727
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sargramostim for active Crohn's disease.
    Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group.
    N Engl J Med; 2005 May 26; 352(21):2193-201. PubMed ID: 15917384
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group.
    N Engl J Med; 2004 Nov 11; 351(20):2069-79. PubMed ID: 15537905
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 11; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 12. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ.
    Gut; 2009 Oct 11; 58(10):1354-62. PubMed ID: 19505878
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A preliminary study of growth hormone therapy for Crohn's disease.
    Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ.
    N Engl J Med; 2000 Jun 01; 342(22):1633-7. PubMed ID: 10833209
    [Abstract] [Full Text] [Related]

  • 17. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

  • 18. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C, Beau P.
    Gastroenterol Clin Biol; 2008 Feb 06; 32(2):153-7. PubMed ID: 18343615
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 20.